Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Lattice Biologics Ltd V.LBL.H

Alternate Symbol(s):  LBLTF

Lattice Biologics Ltd. is engaged in the business of developing, manufacturing and marketing biologics products to domestic and international markets. The Company’s products are used in a variety of applications including enhancing bone regeneration in dental, spine, and general orthopedic indications. Its acellular dermal matrix is used for dental flaps which is used to close defects post-implantation. The Company’s stem cell-based technology AmnioBoost, is an amniotic fluid concentrate, which can be used to accelerate and enhance bone regeneration for dental post implantation. In addition, its products complimentary to the dental allograft market are amniotic membrane, Demineralized bone matrix (DBM) putty, acellular dermal matrix and cancellous DBM sponges.


TSXV:LBL.H - Post by User

Post by cleareyeon Jul 14, 2020 11:02pm
172 Views
Post# 31268767

Core vs. COVID19

Core vs. COVID19I am interested to know more from those on this board.

Nomoreshells4me, you have a reasonable perspective.

I look at the view from 2016 till now. It appears to me that the company generated income from the core business and made good strides in decreasing GS&A, to the point that they may have shown a positive EBITA this year. Unfortunately, COVID19 quarantine probably wiped 3 months of revenue from the books, and the expenses may have continued.

Long view tells me that there is a revenue generating company here that has a good market in which to grow. Amino-boost may provide some help to those who contract the virus; time and trials will tell us more.

So, I invest for the long view, counting on the core business to be developed.

Thoughts?

Will patience and hard work pay off for this company?



<< Previous
Bullboard Posts
Next >>